Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer

(MedPage Today) -- MADRID -- Chemotherapy's generation-long dominance in first-line advanced urothelial cancer ended with a resounding victory for the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) in...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news